Skip to content
Riskpilot
← Back to search
Sign in
Get full access
Idorsia Pharmaceuticals Nordics AB
AB
Active
Org 5594104522
Gustav Iii:S Boulevard 46, 169 73
Solna
Research and experimental development on natural sciences and engineering
· NACE 7210
Est. 2022
5 employees
Watchlist
Share
Sweden
/
Companies
/
Research and experimental development on natural sciences and engineering
/
Idorsia Pharmaceuticals Nordics AB
Overview
Financials
People & ownership
Related companies
Loading company…
People & ownership
Management
Actively employed in the business
Name
Role
Member since
Current (2)
PG
Per Gustaf Hammar
Chief Auditor
Chief Auditor
2025
BY
Bettina Yvonne Blosse
Chief Executive Officer
Chief Executive Officer
2022
Board of directors
Non-executive oversight
Name
Role
Member since
Current (2)
AD
Antje Doether
Chairman
2024
PA
Patrick Alexander Miller
Board of Directors
2024
Former (3)
AG
Arno Groenewoud
Chairman
2022 – 2024
BH
Bengt Håkan Olovsson
Deputy Board Member
2022 – 2024
DR
Dominique Renato Möhr
Deputy Board Member
2022 – 2024
Shareholders
As of last annual report
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
More on Idorsia Pharmaceuticals Nordics AB
Overview →
Headline figures, risk assessment and company summary
Financials & key figures →
Revenue, EBITDA, balance sheet and 5-year trend
Related companies →
Corporate hierarchy, parent and subsidiary network
